An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant

Transplantation

Volumn 88, Issue 5, 2009, Pages 729-735

  Massoumi, Hatef ^a   Elsiesy, Hussein ^b   Khaitova, Viktoriya ^c   Peterson, Brent ^c   Norkus, Edward ^a   Grewal, Priya ^c   Liu, Lawrence ^c   Chang, Charissa ^c   Bach, Nancy ^c   Schiano, Thomas D ^a,c  

^a OUR LADY OF MERCY MEDICAL CENTER   (United States)

^b KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Liver transplantation; Pegylated interferon

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; SERUM ALBUMIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2B;

ACUTE PANCREATITIS; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ANOREXIA; ARTICLE; BACTERIAL PERITONITIS; CEREBROVASCULAR ACCIDENT; CLOSTRIDIUM DIFFICILE INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEPATITIS C; HUMAN; HYPOKALEMIA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; MYASTHENIA LIKE SYNDROME; PNEUMONIA; PRIORITY JOURNAL; RECURRENT INFECTION; SCORING SYSTEM; THROMBOCYTOPENIA; TYPHLITIS; URINARY TRACT INFECTION; VOMITING; DRUG ADMINISTRATION; HEPATITIS C VIRUS; METABOLISM; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 70349582718     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b2e0d1     Document Type: Article

References (33)

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35.
3. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777.
4. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331.
5. Heathcote EJ, Shiftman ML, Cookslcy WG, et al. Peginterferon alfa-2a in patients with, chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673.
6. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: S185.
7. Abergel A, Hezode C, Leroy V, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: A multicentre randomized controlled trial comparing two doses of peginterferon alph-2b. J Viral Hepat 2006; 13: 811.
8. Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: Clinical and therapeutical issues. J Viral Hepat 2000; 7: 87. (Pubitemid 30177098)
9. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: A role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905. (Pubitemid 37098838)
10. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28. (Pubitemid 37408000)
11. Braun M, Vierling JM. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl 2003; 9: S79. (Pubitemid 37408009)
12. Stanca CM, Fiel MI, Kontorinis N, et al. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007; 84: 180. (Pubitemid 47205751)
13. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255. (Pubitemid 41061075)
14. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225.
15. Strader DB, Wright T, Thomas DL, et al; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147.
16. Department of Veterans Affairs Hepatitis C Resource Center; Yee HS, Currie SL, Darling JM, et al. Management and treatment of hepatitis C viral infection: Recommendations from the Department of Veterans Affairs hepatitis C resource center program and the national hepatitis C program office. Am J Gastroenterol 2006; 101: 2360.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEngl J Med 2002; 347:975.
18. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003; 7: 585. (Pubitemid 37093420)
19. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001 ; 358:958.
20. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389. (Pubitemid 37070256)
21. Bruno S, Stroffolini T, Colombo M, et al; Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45: 579.
22. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: Natural history and treatment. Semin Liver Dis 2006; 26: 142.
23. Everson GT, Hoefs JC, Seeff LB, et al; HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675.
24. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350. (Pubitemid 34467369)
25. Weisner RH, Sorrel M, Villamil F; International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1.
26. McHutchison JG, Dusheiko G, Shiftman ML; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227. (Pubitemid 350190753)
27. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. J Hepatol 2007; 46: 206. (Pubitemid 44959155)
28. Helbling B, Jochum W, Stamenic I, et al; Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: Randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762.
29. Afdhal NH, Dieterich DT, Pockros PJ, et al; Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302.
30. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006; 44: 1598.
31. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273. (Pubitemid 35253446)
32. Herrera JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008; 14:272.
33. DiBisceglie AM, Shiftman ML, Everson GT, et al. Prolonged antiviral therapy with Peginterferon to prevent complications of advanced liver diseases associated with hepatitis C: Results of the Hepatitis C long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2007; 46:290A.